Message resonance gains ground as a practical measure of client confidence

Tern plc

Companies are placing greater weight on message resonance as a direct indicator of whether their communications are working. The focus is shifting away from volume-based metrics such as reach and impressions towards whether audiences actually understand and trust what is being said.

This change has clear implications for investors. Message resonance provides a more actionable signal of how well a company is positioned with its audience. Strong alignment between messaging and audience expectations can support client retention and reduce reputational risk, while weak resonance may point to gaps in strategy or execution.

The relevance of this metric is most evident in sectors where trust plays a central role. In regulated or complex markets, unclear or ineffective communication can undermine confidence and delay decision making. Companies that can demonstrate consistent, credible messaging are more likely to maintain stable relationships with clients and stakeholders.

From a commercial perspective, message resonance links communication directly to outcomes. It reflects whether messaging influences perception in a way that supports business objectives. This creates a clearer line between communication spend and return, which is increasingly important in tighter operating environments.

The measurement of message resonance typically combines multiple data sources, including audience behaviour and feedback across digital channels. This allows companies to adjust messaging quickly, improving effectiveness over time.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Search